{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:34:38Z","timestamp":1792708478279,"version":"4.5.0"},"reference-count":273,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemistry"],"published-print":{"date-parts":[[2025,4,15]]},"DOI":"10.1021\/acs.biochem.4c00722","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T23:17:15Z","timestamp":1743549435000},"page":"1698-1719","source":"Crossref","is-referenced-by-count":4,"title":["Rare Diseases, Spotlighting Amyotrophic Lateral Sclerosis, Huntington\u2019s Disease, and Myasthenia Gravis: Insights from Landscape Analysis of Current Research"],"prefix":"10.1021","volume":"64","author":[{"given":"Kavita A.","family":"Iyer","sequence":"first","affiliation":[{"name":"CAS, A Division of the American Chemical Society","place":["Columbus, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-6832","authenticated-orcid":true,"given":"Rumiana","family":"Tenchov","sequence":"additional","affiliation":[{"name":"CAS, A Division of the American Chemical Society","place":["Columbus, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-5184","authenticated-orcid":true,"given":"Janet M.","family":"Sasso","sequence":"additional","affiliation":[{"name":"CAS, A Division of the American Chemical Society","place":["Columbus, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krittika","family":"Ralhan","sequence":"additional","affiliation":[{"name":"ACS International India Pvt. Ltd.","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotsna","family":"Jotshi","sequence":"additional","affiliation":[{"name":"ACS International India Pvt. Ltd.","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitrii","family":"Polshakov","sequence":"additional","affiliation":[{"name":"CAS, A Division of the American Chemical Society","place":["Columbus, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankush","family":"Maind","sequence":"additional","affiliation":[{"name":"ACS International India Pvt. Ltd.","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6711-369X","authenticated-orcid":true,"given":"Qiongqiong Angela","family":"Zhou","sequence":"additional","affiliation":[{"name":"CAS, A Division of the American Chemical Society","place":["Columbus, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"ref1\/cit1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062126"},{"key":"ref2\/cit2","unstructured":"National Organization for Rare Disorders. https:\/\/rarediseases.org\/ (accessed Mar 21, 2024)."},{"key":"ref3\/cit3","unstructured":"Rare Disease\nDatabase. https:\/\/rarediseases.org\/rare-diseases\/ (accessed Mar 21, 2024)."},{"key":"ref4\/cit4","unstructured":"Genetic and\nRare Diseases Information Center. https:\/\/rarediseases.info.nih.gov\/ (accessed Mar 21, 2024)."},{"key":"ref5\/cit5","unstructured":"Rare diseases. https:\/\/research-and-innovation.ec.europa.eu\/research-area\/health\/rare-diseases_en (accessed Mar 21, 2024)."},{"key":"ref6\/cit6","unstructured":"Global Genes. https:\/\/globalgenes.org\/ (accessed\nMar 21, 2024)."},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1113086"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-019-0508-0"},{"key":"ref9\/cit9","unstructured":"Joszt, L. Not So Rare: 300 Million People Worldwide Affected by Rare Diseases. https:\/\/www.ajmc.com\/view\/not-so-rare-300-million-people-worldwide-affected-by-rare-diseases (accessed Mar 27, 2024)."},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.06.031518"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3654"},{"key":"ref12\/cit12","unstructured":"Roberts, A., Wadhwa, R.\n                      Orphan Drug Approval Laws\n                      . https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572052\/ (accessed Mar 26, 2024)."},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002191"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02790-7"},{"key":"ref15\/cit15","unstructured":"Orphan drugs incentives and guidelines in\n2023. https:\/\/within3.com\/blog\/orphan-drug-incentives-guidelines (accessed\nMar 26, 2024)."},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-33"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.744532"},{"key":"ref18\/cit18","unstructured":"CAS Content Collection. https:\/\/www.cas.org\/about\/cas-content (accessed Mar 31, 2024)."},{"key":"ref19\/cit19","unstructured":"CAS REGISTRY. https:\/\/www.cas.org\/cas-data\/cas-registry (accessed Jul 26, 2024)."},{"key":"ref20\/cit20","unstructured":"SciFinder-n. https:\/\/www.cas.org\/solutions\/cas-scifinder-discovery-platform\/cas-scifinder (accessed Mar 30, 2025)."},{"key":"ref21\/cit21","unstructured":"CAS STNext. https:\/\/www.cas.org\/training\/solution\/stn (accessed Jul 25, 2024)."},{"key":"ref22\/cit22","unstructured":"Multiple sclerosis. https:\/\/www.mayoclinic.org\/diseases-conditions\/multiple-sclerosis\/symptoms-causes\/syc-20350269#:~:text=Multiple%20sclerosis%20(MS)%20is%20a,the%20rest%20of%20your%20body. (accessed 11th March, 2024)."},{"key":"ref23\/cit23","unstructured":"Systemic\nLupus Erythematosus (SLE). https:\/\/www.cdc.gov\/lupus\/about\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/lupus\/facts\/detailed.html (accessed Mar 30, 2025)."},{"key":"ref24\/cit24","unstructured":"Scleroderma. https:\/\/www.mayoclinic.org\/diseases-conditions\/scleroderma\/symptoms-causes\/syc-20351952 (accessed 11th March, 2024)."},{"key":"ref25\/cit25","unstructured":"Sjogren\u2019s\nsyndrome. https:\/\/www.mayoclinic.org\/diseases-conditions\/sjogrens-syndrome\/symptoms-causes\/syc-20353216 (accessed 11th March, 2024)."},{"key":"ref26\/cit26","unstructured":"Cystic\nfibrosis. https:\/\/www.mayoclinic.org\/diseases-conditions\/cystic-fibrosis\/symptoms-causes\/syc-20353700#:~:text=Cystic%20fibrosis%20is%20a%20disorder,mucus%2C%20sweat%20and%20digestive%20juices. (accessed 11th March, 2024)."},{"key":"ref27\/cit27","unstructured":"Sickle\ncell anemia. https:\/\/www.mayoclinic.org\/diseases-conditions\/sickle-cell-anemia\/symptoms-causes\/syc-20355876 (accessed 11th March, 2024)."},{"key":"ref28\/cit28","unstructured":"Multiple\nmyeloma. https:\/\/www.mayoclinic.org\/diseases-conditions\/multiple-myeloma\/symptoms-causes\/syc-20353378#:~:text=Multiple%20myeloma%20is%20a%20cancer,build%20up%20in%20bone%20marrow. (accessed 11th March, 2024)."},{"key":"ref29\/cit29","unstructured":"Non-Hodgkin\nLymphoma Treatment (PDQ\u00ae)\u2013Patient Version. https:\/\/www.cancer.gov\/types\/lymphoma\/patient\/adult-nhl-treatment-pdq#:~:text=Non%2DHodgkin%20lymphoma%20is%20a,risk%20of%20non%2DHodgkin%20lymphoma. (accessed 11th March, 2024)."},{"key":"ref30\/cit30","unstructured":"Acute\nmyelogenous leukemia. https:\/\/www.mayoclinic.org\/diseases-conditions\/acute-myelogenous-leukemia\/symptoms-causes\/syc-20369109 (accessed 11th March, 2024)."},{"key":"ref31\/cit31","unstructured":"Pheochromocytoma. https:\/\/www.cancer.gov\/pediatric-adult-rare-tumor\/rare-tumors\/rare-endocrine-tumor\/pheochromocytoma#:~:text=Pheochromocytoma%20is%20a%20type%20of,on%20top%20of%20the%20kidneys. (accessed 11th March, 2024)."},{"key":"ref32\/cit32","unstructured":"Cholangiocarcinoma\n(bile duct cancer). https:\/\/www.mayoclinic.org\/diseases-conditions\/cholangiocarcinoma\/symptoms-causes\/syc-20352408 (accessed 11th March, 2024)."},{"key":"ref33\/cit33","unstructured":"Melanoma. https:\/\/www.mayoclinic.org\/diseases-conditions\/melanoma\/symptoms-causes\/syc-20374884#:~:text=deeper%20skin%20layers.Melanoma%20is%20a%20kind%20of%20skin%20cancer%20that%20starts%20in,often%20exposed%20to%20the%20sun. (accessed 11th March, 2024)."},{"key":"ref34\/cit34","unstructured":"Liver\ncancer. https:\/\/www.mayoclinic.org\/diseases-conditions\/liver-cancer\/symptoms-causes\/syc-20353659 (accessed 11th March, 2024)."},{"key":"ref35\/cit35","unstructured":"Mesothelioma. https:\/\/www.mayoclinic.org\/diseases-conditions\/mesothelioma\/symptoms-causes\/syc-20375022 (accessed 11th March, 2024)."},{"key":"ref36\/cit36","unstructured":"Glioma. https:\/\/www.mayoclinic.org\/diseases-conditions\/glioblastoma\/cdc-20350148 (accessed 11th March, 2024)."},{"key":"ref37\/cit37","unstructured":"Creutzfeldt-Jakob\ndisease. https:\/\/www.mayoclinic.org\/diseases-conditions\/creutzfeldt-jakob-disease\/symptoms-causes\/syc-20371226 (accessed 11th March, 2024)."},{"key":"ref38\/cit38","unstructured":"Progressive\nsupranuclear palsy. https:\/\/www.mayoclinic.org\/diseases-conditions\/progressive-supranuclear-palsy\/symptoms-causes\/syc-20355659 (accessed 11th March, 2024)."},{"key":"ref39\/cit39","unstructured":"Graves\u2019\ndisease. https:\/\/www.mayoclinic.org\/diseases-conditions\/graves-disease\/symptoms-causes\/syc-20356240 (accessed 11th March, 2024)."},{"key":"ref40\/cit40","unstructured":"Juvenile\nidiopathic arthritis. https:\/\/www.mayoclinic.org\/diseases-conditions\/juvenile-idiopathic-arthritis\/symptoms-causes\/syc-20374082 (accessed 11th March, 2024)."},{"key":"ref41\/cit41","unstructured":"Sarcoidosis. https:\/\/www.mayoclinic.org\/diseases-conditions\/sarcoidosis\/symptoms-causes\/syc-20350358 (accessed 11th March, 2024)."},{"key":"ref42\/cit42","unstructured":"Guillain-Barre\nsyndrome. https:\/\/www.mayoclinic.org\/diseases-conditions\/guillain-barre-syndrome\/symptoms-causes\/syc-20362793 (accessed 11th March, 2024)."},{"key":"ref43\/cit43","unstructured":"Kaposi\nsarcoma. https:\/\/www.mayoclinic.org\/diseases-conditions\/kaposis-sarcoma\/cdc-20387726 (accessed 11th March, 2024)."},{"key":"ref44\/cit44","unstructured":"Thyroid\ncancer. https:\/\/www.mayoclinic.org\/diseases-conditions\/thyroid-cancer\/symptoms-causes\/syc-20354161 (accessed 11th March, 2024)."},{"key":"ref45\/cit45","unstructured":"Esophageal\ncancer. https:\/\/www.mayoclinic.org\/diseases-conditions\/esophageal-cancer\/symptoms-causes\/syc-20356084#:~:text=Esophageal%20cancer%20occurs%20when%20cells,other%20parts%20of%20the%20body. (accessed 11th March, 2024)."},{"key":"ref46\/cit46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61156-7"},{"key":"ref47\/cit47","volume-title":"Gene Reviews","author":"Siddique N.","year":"2023"},{"key":"ref48\/cit48","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-3"},{"key":"ref49\/cit49","unstructured":"Amyotrophic lateral sclerosis (ALS). https:\/\/www.mayoclinic.org\/diseases-conditions\/amyotrophic-lateral-sclerosis\/symptoms-causes\/syc-20354022#:~:text=ALS%20often%20begins%20with%20muscle,cure%20for%20this%20fatal%20disease. (accessed Feb 26, 2024)."},{"key":"ref50\/cit50","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00465-8"},{"key":"ref51\/cit51","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00414-2"},{"key":"ref52\/cit52","unstructured":"Barbieri, E. Epidemiology of ALS: Incidence, Prevalence, and Suspected Clusters. https:\/\/www.targetals.org\/2022\/11\/22\/epidemiology-of-als-incidence-prevalence-and-clusters\/#:~:text=How%20common%20is%20ALS%20worldwide,100%2C000%20to%206%20per%20100%2C000. (accessed Feb 26, 2024)."},{"key":"ref53\/cit53","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207474"},{"key":"ref54\/cit54","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09652-y"},{"key":"ref55\/cit55","unstructured":"ALS Ice Bucket Challenge. https:\/\/www.als.org\/IBC (accessed\nMar 18. 2024)."},{"key":"ref56\/cit56","unstructured":"Piper, K. The Ice Bucket Challenge and the promise \u2500 and the pitfalls \u2500 of viral charity. https:\/\/www.vox.com\/future-perfect\/2019\/7\/20\/20699732\/ice-bucket-challenge-viral-charity-als (accessed Mar 18, 2024)."},{"key":"ref57\/cit57","unstructured":"Ice Bucket Challenge\ndramatically accelerated the fight against ALS. https:\/\/www.als.org\/stories-news\/ice-bucket-challenge-dramatically-accelerated-fight-against-als (accessed Mar 18, 2024)."},{"key":"ref58\/cit58","unstructured":"Onque, R. The \u2018Ice Bucket Challenge\u2019 funded a new ALS drug, but experts have varying opinions about its approval. https:\/\/www.cnbc.com\/2022\/10\/08\/ice-bucket-challenge-new-als-drug-approved-with-funds-raised.html (accessed Mar 18, 2024)."},{"key":"ref59\/cit59","unstructured":"Who Gets ALS? https:\/\/www.als.org\/understanding-als\/who-gets-als (accessed Mar 18, 2024)."},{"key":"ref60\/cit60","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2011.150"},{"key":"ref61\/cit61","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2014.10.009"},{"key":"ref62\/cit62","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3584"},{"key":"ref63\/cit63","unstructured":"ALS Genes and Mutations. https:\/\/www.als.org\/research\/als-research-topics\/genetics (accessed Feb 26, 2024)."},{"key":"ref64\/cit64","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024125"},{"key":"ref65\/cit65","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01310"},{"key":"ref66\/cit66","doi-asserted-by":"publisher","DOI":"10.1126\/science.1165942"},{"key":"ref67\/cit67","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-996-0008-9"},{"key":"ref68\/cit68","unstructured":"Amyotrophic Lateral Sclerosis (ALS): Causes\/Inheritance. https:\/\/www.mda.org\/disease\/amyotrophic-lateral-sclerosis\/causes-inheritance#:~:text=SOD1%20was%20the%20first%20gene,that%20can%20cause%20familial%20ALS. (accessed Feb 26, 2024)."},{"key":"ref69\/cit69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03891-8"},{"key":"ref70\/cit70","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu068"},{"key":"ref71\/cit71","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr366"},{"key":"ref72\/cit72","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.09.011"},{"key":"ref73\/cit73","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70043-1"},{"key":"ref74\/cit74","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2012.98"},{"key":"ref75\/cit75","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2012-129036"},{"key":"ref76\/cit76","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70071-1"},{"key":"ref77\/cit77","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2021.05.017"},{"key":"ref78\/cit78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1810413115"},{"key":"ref79\/cit79","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181bbff05"},{"key":"ref80\/cit80","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0658-x"},{"key":"ref81\/cit81","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.841394"},{"key":"ref82\/cit82","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020412"},{"key":"ref83\/cit83","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.250"},{"key":"ref84\/cit84","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2013.184"},{"key":"ref85\/cit85","unstructured":"Wexler, M. Sporadic ALS. https:\/\/alsnewstoday.com\/sporadic-als\/ (accessed Feb 26, 2024)."},{"key":"ref86\/cit86","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.851496"},{"key":"ref87\/cit87","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1170996"},{"key":"ref88\/cit88","doi-asserted-by":"publisher","DOI":"10.1111\/cge.12117"},{"key":"ref89\/cit89","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad087"},{"key":"ref90\/cit90","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01394-6"},{"key":"ref91\/cit91","unstructured":"Breakthrough that can halt the progression of ALS\ndeveloped by Northeastern\nscientist. https:\/\/news.northeastern.edu\/2024\/01\/30\/als-progression-treatment-strategy\/ (accessed Jul 2, 2024)."},{"key":"ref92\/cit92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002462"},{"key":"ref93\/cit93","unstructured":"Neurofilament Light Chain: A Biomarker for\nALS Progression? https:\/\/www.als.net\/news\/neurofilament-light-chain\/#:~:text=NfL%20is%20often%20called%20a%20nonspecific%20biomarker,brain%20injuries%2C%20multiple%20sclerosis%2C%20and%20Alzheimer%27s%20disease.&text=However%2C%20an%20observed%20increase%20in%20the%20level,symptoms%20for%20people%20with%20ALS%2Drelated%20genetic%20mutations. (accessed Mar 30, 2025)."},{"key":"ref94\/cit94","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.679199"},{"key":"ref95\/cit95","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.753242"},{"key":"ref96\/cit96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01499-6"},{"key":"ref97\/cit97","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-398270-4.00020-3"},{"key":"ref98\/cit98","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-373861-5.00018-7"},{"key":"ref99\/cit99","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-63233-3.00017-8"},{"key":"ref100\/cit100","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012373960-5.00020-4"},{"key":"ref101\/cit101","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13413"},{"key":"ref102\/cit102","unstructured":"Huntington\u2019s disease. https:\/\/www.mayoclinic.org\/diseases-conditions\/huntingtons-disease\/diagnosis-treatment\/drc-20356122 (accessed Feb 12, 2024)."},{"key":"ref103\/cit103","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2021-003074"},{"key":"ref104\/cit104","unstructured":"Huntington disease (HD) epidemiology. https:\/\/www.rarediseaseadvisor.com\/disease-info-pages\/huntington-disease-epidemiology\/#:~:text=They%20estimated%20that%20the%20global,around%202.7%20per%20100%2C000%20persons.&text=In%202022%2C%20researchers%20published%20an,between%202010%20and%20February%202022. (accessed Feb 26, 2024)."},{"key":"ref105\/cit105","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1686"},{"key":"ref106\/cit106","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3772"},{"key":"ref107\/cit107","unstructured":"Ramakrishnan, S.; Gupta, V. Trinucleotide Repeat Disorders. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559254\/ (accessed Feb 14, 2024)."},{"key":"ref108\/cit108","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-374984-0.01580-1"},{"key":"ref109\/cit109","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024240"},{"key":"ref110\/cit110","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-381328-2.00015-8"},{"key":"ref111\/cit111","unstructured":"Huntington\u2019s Disease. https:\/\/www.ninds.nih.gov\/health-information\/disorders\/huntingtons-disease#:~:text=Early%20signs%20of%20HD%20can,increases%20the%20chances%20of%20falling. (accessed Feb 26, 2024)."},{"key":"ref112\/cit112","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-381328-2.00014-6"},{"key":"ref113\/cit113","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.25.9.589"},{"key":"ref114\/cit114","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002858"},{"key":"ref115\/cit115","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/6.5.775"},{"key":"ref116\/cit116","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003527"},{"key":"ref117\/cit117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.0030082"},{"key":"ref118\/cit118","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.003"},{"key":"ref119\/cit119","doi-asserted-by":"publisher","DOI":"10.1186\/gm80"},{"key":"ref120\/cit120","doi-asserted-by":"publisher","DOI":"10.2217\/fnl.11.65"},{"key":"ref121\/cit121","unstructured":"Huntington\u2019s Disease: The Discovery\nof the Huntingtin Gene. https:\/\/www.nature.com\/scitable\/topicpage\/huntington-s-disease-the-discovery-of-the-851\/#:~:text=It%20turns%20out%20that%20the,an%20individual%20will%20have%20HD. (accessed Apr 10, 2024)."},{"key":"ref122\/cit122","unstructured":"HTT gene. https:\/\/medlineplus.gov\/genetics\/gene\/htt\/ (accessed Apr 10, 2024)."},{"key":"ref123\/cit123","unstructured":"Huntington\u2019s\ndisease. https:\/\/medlineplus.gov\/genetics\/condition\/huntingtons-disease\/ (accessed Apr 10, 2024)."},{"key":"ref124\/cit124","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"ref125\/cit125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.02.003"},{"key":"ref126\/cit126","unstructured":"Genetic Testing Protocol for Huntington\u2019s Disease. https:\/\/hdsa.org\/wp-content\/uploads\/2015\/02\/HDSA-Gen-Testing-Protocol-for-HD.pdf (accessed Feb 26, 2024)."},{"key":"ref127\/cit127","unstructured":"Huntington\u2019s\ndisease: Genetic Testing and Counseling. https:\/\/huntingtonsdiseasenews.com\/genetic-testing-and-counseling\/ (accessed Feb 26, 2024)."},{"key":"ref128\/cit128","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-023-01334-z"},{"key":"ref129\/cit129","unstructured":"Shifting the paradigm \u2013 novel approaches\nto amyotrophic lateral\nsclerosis therapy. https:\/\/www.pharmaceutical-technology.com\/analyst-comment\/shifting-the-paradigm-novel-approaches-to-amyotrophic-lateral-sclerosis-therapy\/ (accessed Jul 2, 2024)."},{"key":"ref130\/cit130","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01093-3"},{"key":"ref131\/cit131","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00695-3"},{"key":"ref132\/cit132","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.70217"},{"key":"ref133\/cit133","unstructured":"Myasthenia gravis. https:\/\/www.mayoclinic.org\/diseases-conditions\/myasthenia-gravis\/symptoms-causes\/syc-20352036 (accessed Mar 18, 2024)."},{"key":"ref134\/cit134","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00604"},{"key":"ref135\/cit135","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/874680"},{"key":"ref136\/cit136","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2005.08.007"},{"key":"ref137\/cit137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.011"},{"key":"ref138\/cit138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212"},{"key":"ref139\/cit139","doi-asserted-by":"publisher","DOI":"10.1016\/B978-032303506-4.10221-4"},{"key":"ref140\/cit140","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4160-3206-9.10064-3"},{"key":"ref141\/cit141","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-407-00058-2.50026-7"},{"key":"ref142\/cit142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.003"},{"key":"ref143\/cit143","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304057"},{"key":"ref144\/cit144","doi-asserted-by":"publisher","DOI":"10.7326\/L20-0845"},{"key":"ref145\/cit145","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-022-00516-3"},{"key":"ref146\/cit146","unstructured":"Myasthenia gravis epidemiology. https:\/\/www.rarediseaseadvisor.com\/disease-info-pages\/myasthenia-gravis-epidemiology\/#:~:text=Global%20prevalence%20rates%20range%20from%20150%20to%20200%20cases%20per%201%2C000%2C000%20people.&text=The%20prevalence%20of%20MG%20in,between%2036%2C000%20and%2060%2C000%20cases.&text=In%20Europe%2C%20an%20estimated%2056%2C000%20to%20123%2C000%20individuals%20live%20with%20MG. (accessed Feb 26 2024)."},{"key":"ref147\/cit147","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235"},{"key":"ref148\/cit148","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102349"},{"key":"ref149\/cit149","doi-asserted-by":"publisher","DOI":"10.1186\/s13317-019-0124-6"},{"key":"ref150\/cit150","doi-asserted-by":"publisher","DOI":"10.1007\/BF02115001"},{"key":"ref151\/cit151","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000218159.79769.5c"},{"key":"ref152\/cit152","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.001"},{"key":"ref153\/cit153","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/404053"},{"key":"ref154\/cit154","first-page":"3","volume":"2","author":"Bao S.","year":"2016","journal-title":"J. Autoimmune Disord"},{"key":"ref155\/cit155","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S146617"},{"key":"ref156\/cit156","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.1.38"},{"key":"ref157\/cit157","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-021-01204-x"},{"key":"ref158\/cit158","doi-asserted-by":"publisher","DOI":"10.1159\/000452954"},{"key":"ref159\/cit159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.667336"},{"key":"ref160\/cit160","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03306-3"},{"key":"ref161\/cit161","unstructured":"Westerberg, E.\n                      Environmental Factors of Importance in Myasthenia Gravis. Emphasis on Physical Activity\n                      . Ph.D. Thesis, Uppsala University, Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 1439, 2018."},{"key":"ref162\/cit162","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y"},{"key":"ref163\/cit163","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-024-00783-w"},{"key":"ref164\/cit164","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52539-w"},{"key":"ref165\/cit165","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00538"},{"key":"ref166\/cit166","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S377056"},{"key":"ref167\/cit167","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27863-2"},{"key":"ref168\/cit168","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12015"},{"key":"ref169\/cit169","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09799-z"},{"key":"ref170\/cit170","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266529"},{"key":"ref171\/cit171","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2013.775309"},{"key":"ref172\/cit172","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-012-0089-5"},{"key":"ref173\/cit173","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002757"},{"key":"ref174\/cit174","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15151"},{"key":"ref175\/cit175","doi-asserted-by":"crossref","first-page":"P02.147","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P02.147","volume":"78","author":"Rahmlow M.","year":"2012","journal-title":"Neurology"},{"key":"ref176\/cit176","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1556-3"},{"key":"ref177\/cit177","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00079"},{"key":"ref178\/cit178","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11418-y"},{"key":"ref179\/cit179","first-page":"A43","volume":"89","author":"Fung W. L. A.","year":"2018","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"ref180\/cit180","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2015.05.006"},{"key":"ref181\/cit181","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-019-01102-w"},{"key":"ref182\/cit182","unstructured":"Myasthenia\ngravis - Comorbidities. https:\/\/www.rarediseaseadvisor.com\/disease-info-pages\/myasthenia-gravis-comorbidities\/#:~:text=Thyroid%20disease%2C%20systemic%20lupus%20erythematosus,not%20pose%20a%20significant%20risk. (accessed Mar 15, 2024)."},{"key":"ref183\/cit183","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12599"},{"key":"ref184\/cit184","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9562.1000317"},{"key":"ref185\/cit185","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2008.10.030"},{"key":"ref186\/cit186","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132066"},{"key":"ref187\/cit187","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.04.008"},{"key":"ref188\/cit188","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00751-5"},{"key":"ref189\/cit189","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184388"},{"key":"ref190\/cit190","unstructured":"Huntington\u2019s Disease: Gene Therapy\nApproaches. https:\/\/patienteducation.asgct.org\/disease-treatments\/huntingtons-disease (accessed Mar 3, 2025)."},{"key":"ref191\/cit191","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9784-8_17"},{"key":"ref192\/cit192","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0110-z"},{"key":"ref193\/cit193","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2023.04.017"},{"key":"ref194\/cit194","doi-asserted-by":"publisher","DOI":"10.5607\/en.2013.22.1.1"},{"key":"ref195\/cit195","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-016-9677-6"},{"key":"ref196\/cit196","unstructured":"Study: Common Gout Medication Reduces Risk\nof Alzheimer\u2019s,\nParkinson\u2019s, ALS. https:\/\/www.barrowneuro.org\/about\/news-and-articles\/press-releases\/study-common-gout-medication-reduces-risk-of-alzheimers-parkinsons-als\/ (accessed Mar 19, 2024)."},{"key":"ref197\/cit197","unstructured":"Wexler, M. Gout medication decreases risk of ALS and other diseases: Study. https:\/\/alsnewstoday.com\/news\/gout-medication-decreases-risk-als-other-diseases-study\/ (accessed Mar 19, 2024)."},{"key":"ref198\/cit198","unstructured":"Myasthenia Gravis\nTreatment. https:\/\/www.umms.org\/ummc\/health-services\/neurology\/services\/myasthenia-gravis\/treatment#:~:text=Immunosuppressant%20medications%20work%20to%20lower,%2C%20Azathioprine%2C%20and%20Mycophenolate%20Mofetil. (accessed Mar 20, 2024)."},{"key":"ref199\/cit199","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102712"},{"key":"ref200\/cit200","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903518107"},{"key":"ref201\/cit201","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0810"},{"key":"ref202\/cit202","unstructured":"What Medications Help Treat Myasthenia\nGravis? https:\/\/www.healthline.com\/health\/myasthenia-gravis\/medication-for-myasthenia-gravis (accessed Mar 20, 2024)."},{"key":"ref203\/cit203","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06062-w"},{"key":"ref204\/cit204","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887"},{"key":"ref205\/cit205","doi-asserted-by":"publisher","DOI":"10.3390\/ph11020044"},{"key":"ref206\/cit206","first-page":"545","volume":"3","author":"Paleacu D.","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref207\/cit207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1982.tb03060.x"},{"key":"ref208\/cit208","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0670-4"},{"key":"ref209\/cit209","doi-asserted-by":"publisher","DOI":"10.1080\/10401230701844802"},{"key":"ref210\/cit210","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.47.1.70"},{"key":"ref211\/cit211","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13030416"},{"key":"ref212\/cit212","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e3283168d1d"},{"key":"ref213\/cit213","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157781"},{"key":"ref214\/cit214","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00513-7"},{"key":"ref215\/cit215","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg7162"},{"key":"ref216\/cit216","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00503-x"},{"key":"ref217\/cit217","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-230569"},{"key":"ref218\/cit218","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-220557"},{"key":"ref219\/cit219","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.386406"},{"key":"ref220\/cit220","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(00)00391-2"},{"key":"ref221\/cit221","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2019.00258"},{"key":"ref222\/cit222","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2020.101973"},{"key":"ref223\/cit223","doi-asserted-by":"publisher","DOI":"10.3390\/biology12101307"},{"key":"ref224\/cit224","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104963"},{"key":"ref225\/cit225","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00193"},{"key":"ref226\/cit226","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00486"},{"key":"ref227\/cit227","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2018.00401"},{"key":"ref228\/cit228","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-022-00193-y"},{"key":"ref229\/cit229","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.11.026"},{"key":"ref230\/cit230","doi-asserted-by":"publisher","DOI":"10.3390\/cells12111450"},{"key":"ref231\/cit231","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurop.2023.100117"},{"key":"ref232\/cit232","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2017.05.002"},{"key":"ref233\/cit233","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt036"},{"key":"ref234\/cit234","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq212"},{"key":"ref235\/cit235","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03111-7"},{"key":"ref236\/cit236","doi-asserted-by":"publisher","DOI":"10.3389\/fnetp.2023.1205544"},{"key":"ref237\/cit237","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00278"},{"key":"ref238\/cit238","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00242"},{"key":"ref239\/cit239","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa309"},{"key":"ref240\/cit240","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01588-0"},{"key":"ref241\/cit241","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010261"},{"key":"ref242\/cit242","doi-asserted-by":"crossref","unstructured":"Rothstein, J. D.; Diamond, B.\n                      The role of NG2 glial cells in ALS pathogenesis\n                      ; Johns Hopkins University, Oct 2013.","DOI":"10.21236\/ADA598910"},{"key":"ref243\/cit243","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11758"},{"key":"ref244\/cit244","unstructured":"Clinical Trials. https:\/\/www.clinicaltrials.gov\/ (accessed Apr 4, 2024)."},{"key":"ref245\/cit245","unstructured":"BERRY, J. D. Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG\/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis. https:\/\/reporter.nih.gov\/search\/mCZMWkS8p06HsrP6zbfaTg\/project-details\/10834469 (accessed Apr 4, 2024)."},{"key":"ref246\/cit246","unstructured":"RAPA-501 Therapy\nfor ALS. https:\/\/clinicaltrials.gov\/study\/NCT04220190 (accessed Apr 4, 2024)."},{"key":"ref247\/cit247","unstructured":"Safety, Tolerability,\nand Efficacy Study of Intrathecally Administered\nGene Therapy AMT-162 in Amyotrophic Lateral Sclerosis (ALS) Patients\nWith SOD1Mutations. https:\/\/clinicaltrials.gov\/study\/NCT06100276 (accessed Apr 4, 2024)."},{"key":"ref248\/cit248","unstructured":"FB1006: AI-discovered\ndrug advances to clinical trials for ALS treatment. https:\/\/www.news-medical.net\/news\/20240227\/FB1006-AI-discovered-drug-advances-to-clinical-trials-for-ALS-treatment.aspx (accessed Apr 4, 2024)."},{"key":"ref249\/cit249","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102672"},{"key":"ref250\/cit250","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.90.15_supplement.P6.465"},{"key":"ref251\/cit251","unstructured":"MN-166 Ibudilast (Progressive Multiple\nSclerosis, Amyotrophic Lateral\nSclerosis, and Drug Dependence). https:\/\/medicinova.com\/clinical-development\/core\/mn-166\/?doing_wp_cron=1712224628.1748700141906738281250 (accessed Apr 4, 2024)."},{"key":"ref252\/cit252","unstructured":"FDA Grants Fast\nTrack Designation for MediciNova\u2019s MN-166\n(ibudilast) for Progressive Multiple Sclerosis. https:\/\/investors.medicinova.com\/news-releases\/news-release-details\/fda-grants-fast-track-designation-medicinovas-mn-166-ibudilast-1 (accessed Apr 4, 2024)."},{"key":"ref253\/cit253","unstructured":"Ibudilast. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=445814 (accessed Apr 4, 2024)."},{"key":"ref254\/cit254","unstructured":"Prilenia Announces\nTopline Results for Pridopidine in Phase 2 ALS\nStudy. https:\/\/s202.q4cdn.com\/210612175\/files\/doc_news\/Prilenia-Announces-Topline-Results-for-Pridopidine-in-Phase-2-ALS-Study-2023.pdf (accessed Apr 4, 2024)."},{"key":"ref255\/cit255","unstructured":"About ALS. https:\/\/www.prilenia.com\/what-is-als\/ (accessed Apr 4, 2024)."},{"key":"ref256\/cit256","unstructured":"Wave Life Sciences\nAnnounces Positive Update from Phase 1b\/2a SELECT-HD\nTrial with Initial Results Indicating Allele-Selective Target Engagement\nwith WVE-003 in Huntington\u2019s Disease. https:\/\/www.globenewswire.com\/news-release\/2022\/09\/20\/2519092\/0\/en\/Wave-Life-Sciences-Announces-Positive-Update-from-Phase-1b-2a-SELECT-HD-Trial-with-Initial-Results-Indicating-Allele-Selective-Target-Engagement-with-WVE-003-in-Huntington-s-Diseas.html (accessed Apr 16, 2024)."},{"key":"ref257\/cit257","unstructured":"Efficacy and Safety\nof NestaCell\u00ae in Huntington\u2019s Disease\n(STAR). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06097780 (accessed Apr 4, 2024)."},{"key":"ref258\/cit258","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01919-8"},{"key":"ref259\/cit259","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00313"},{"key":"ref260\/cit260","unstructured":"SAGE THERAPEUTICS PROVIDES IMPORTANT UPDATE ON THE\nCLINICAL DEVELOPMENT\nPROGRAM FOR SAGE\u2019S INVESTIGATIONAL DRUG, SAGE-718. https:\/\/hdsa.org\/news\/sage-therapeutics-provides-important-update-on-the-clinical-development-program-for-sages-investigational-drug-sage-718\/ (accessed Apr 4, 2024)."},{"key":"ref261\/cit261","unstructured":"Sage Therapeutics\nAnnounces U.S. Food and Drug Administration Granted\nSAGE-718 Orphan Drug Designation for the Treatment of Huntington\u2019s\nDisease. https:\/\/investor.sagerx.com\/news-releases\/news-release-details\/sage-therapeutics-announces-us-food-and-drug-administration (accessed Apr 4, 2024)."},{"key":"ref262\/cit262","unstructured":"CNP-106 Myasthenia\nGravis. https:\/\/courpharma.com\/our-clinical-trials\/cnp-106-clinical-trial-myasthenia-gravis\/ (accessed Mar 30, 2025)."},{"key":"ref263\/cit263","doi-asserted-by":"crossref","unstructured":"Chahin, N.; Sahagian, G.; Feinberg, M. H.; Stewart, C. A.; Jewell, C. M.; Kurtoglu, M.; Miljkovi\u0107, M. D.; Vu, T.; Mozaffar, T.; Howard, J. F., Jr. (2024) Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy. medRxiv, 2024.01.03.24300770.","DOI":"10.1101\/2024.01.03.24300770"},{"key":"ref264\/cit264","unstructured":"CARTESIAN THERAPEUTICS\nHIGHLIGHTS PROGRESS AND 2024 STRATEGIC PRIORITIES\nACROSS INNOVATIVE PIPELINE OF MRNA CELL THERAPIES FOR AUTOIMMUNITY. https:\/\/finance.yahoo.com\/news\/cartesian-therapeutics-highlights-progress-2024-121000662.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAALlXgbDHUZfVlYB3oqAP4hXZnuVCki1-nEJS7BSG3plp8Wv2UPsYoq4UsVoeoQxHDcv28U3_nLtf08mAJKuhirkhNELYAk0bcx33kBToEhe5nli5PuQAYpImP6KNaAcHr6NzSyQCLu6gVgP0aPHlezBPY4FLlii99ZAbd6hwibVE (accessed Mar 30, 2025)."},{"key":"ref265\/cit265","unstructured":"RemeGen Releases\nPhase II Clinical Study Data for Treatment of Myasthenia\nGravis in Chinese Patients. https:\/\/www.prnewswire.com\/news-releases\/remegen-releases-phase-ii-clinical-study-data-for-treatment-of-myasthenia-gravis-in-chinese-patients-301664085.html (accessed Apr 4, 2024)."},{"key":"ref266\/cit266","unstructured":"Amylyx Pharmaceuticals\nAnnounces Formal Intention to Remove RELYVRIO\u00ae\/ALBRIOZA\nfrom the Market; Provides Updates on Access to Therapy, Pipeline,\nCorporate Restructuring, and Strategy. https:\/\/www.amylyx.com\/news\/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrior\/albriozatm-from-the-market-provides-updates-on-access-to-therapy-pipeline-corporate-restructuring-and-strategy (accessed Apr 4, 2024)."},{"key":"ref267\/cit267","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2013.114"},{"key":"ref268\/cit268","doi-asserted-by":"publisher","DOI":"10.1534\/g3.115.018564"},{"key":"ref269\/cit269","unstructured":"Whole Exome Sequencing and Analysis. https:\/\/nisc.nih.gov\/docs\/FAQ_whole_exome.pdf (accessed Mar 27, 2024)."},{"key":"ref270\/cit270","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-367-1_12"},{"key":"ref271\/cit271","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-809633-8.20095-2"},{"key":"ref272\/cit272","unstructured":"Global Alliance for Genomics and Health (GA4GH). https:\/\/www.ga4gh.org\/ (accessed Mar 27, 2024)."},{"key":"ref273\/cit273","unstructured":"Undiagnosed\nDiseases Network (UDN). https:\/\/undiagnosed.hms.harvard.edu\/ (accessed Mar 27, 2024)."}],"container-title":["Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.biochem.4c00722","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.biochem.4c00722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T04:10:54Z","timestamp":1744690254000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.biochem.4c00722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":273,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,15]]}},"alternative-id":["10.1021\/acs.biochem.4c00722"],"URL":"https:\/\/doi.org\/10.1021\/acs.biochem.4c00722","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2024-rkqvt-v2","asserted-by":"object"},{"id-type":"doi","id":"10.26434\/chemrxiv-2024-rkqvt","asserted-by":"object"}]},"ISSN":["0006-2960","1520-4995"],"issn-type":[{"value":"0006-2960","type":"print"},{"value":"1520-4995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}